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doi:10.1016/j.kjms.2011.06.014Abstract A 2-week, randomized, parallel-group open trial was designed to evaluate the
safety and tolerability of a rapid initiation regimen with a higher dose of quetiapine (up to
800 mg/d by Day 4) than that used in the conventional initiation regimen of quetiapine (up
to 400 mg/d by Day 5) in patients with schizophrenia or schizoaffective disorders. Forty
patients were recruited and randomly (3:1) assigned to either the group with rapid initiation
of quetiapine or the group with conventional initiation. At the end of the investigation, the
difference between the groups in the incidence of adverse events was not significant; a signif-
icant drop in the Barnes Akathisia Rating Scale and Simpson-Angus Scale scores was observed
only in the group with the rapid initiation regimen. The groups did not differ in terms of
improvement on the Clinical Global ImpressiondSeverity of Illness and Positive and Negative
Syndrome Scale at the end of the study. The results of our 2-week study suggest that rapid
initiation with a higher dose of quetiapine (up to 800 mg/d by Day 4) is well tolerated in
patients with schizophrenia or schizoaffective disorders and does not compromise efficacy
relative to the conventional initiation.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Road, Taipei City Psychiatric Centre, Taipei 110, Taiwan.
.tw (S.-K. Lin).
vier Taiwan LLC. All rights reserved.
Rapid initiation of quetiapine 509Introduction
Quetiapine is a dibenzothiazepine derivative that is used to
treat patients with acute and chronic psychoses, such as
schizophrenia [1]. The initiation regimen that is recom-
mended in the prescribing information for quetiapine and
approved by the regulatory authorities is a 4-day schedule
that involves an initial dose of 50 mg on Day 1, increasing to
300 mg on Day 4 [2]. However, this schedule may be inap-
propriate for acutely ill patients who frequently require
higher doses of quetiapine and rapid initiation of therapy
[3]. If the initiation period of quetiapine could safely be
reduced, acutely ill patients could receive higher doses
within a shorter period than that in current clinical prac-
tice. The results of a recent pilot trial suggest that rapid
initiation with a higher dose of quetiapine (400 mg/d by Day
2) is as safe as the approved initiation schedule and does
not increase adverse effects or vital signs [4].
This study was designed as a pilot trial to determine
whether a rapid dose initiation regimen with a high dose of
quetiapine is safe and well tolerated in patients with acute
schizophrenia or schizoaffective disorders. The objective of
the trial was to evaluate the safety and tolerability of an
initiation schedule that enables acutely ill patients to
receive a dose of up to 800 mg/d of quetiapine by Day 4 (by
comparison with the conventional dose initiation schedule,
in which a dose of 300 mg/d is reached by Day 4). The




Patients who were admitted to acute psychiatric wards with
an acute exacerbation of schizophrenia or schizoaffective
disorder and a Clinical Global ImpressiondSeverity of Illness
(CGI-S) score greater than or equal to 4 were enrolled in the
study. The dose of previous oral antipsychotics was reduced
as soon as possible after the initiation of the quetiapine
treatment. Previously administered antipsychotics were
withdrawn completely by Day 3 at the latest in all cases.
From Day 3 onwards, no antipsychotic medication other
than quetiapine was administered. Any contraindicated
medication, as specified in the country-specific prescribing
information, was prohibited. Psychotropic medications,
including antidepressants and mood stabilizers, which were
taken by the patient at stable doses for at least 4 weeks
before entry into the trial, were continued. The introduc-
tion of any other psychotropic medication during the trial
was prohibited. Patients were excluded if they had been
treated with any depot antipsychotic medication within
1-day dosing interval before being excluded.
Study design
This study was a randomized, parallel-group open trial of two
initiation regimens of quetiapine (rapid vs. conventional). An
open-label design was regarded as sufficient because the
primary objective was safety. Randomization eliminated anyselection bias in the assignment of individuals to the study
and control groups. The rapid dose initiation of quetiapine
was compared with the conventional, recommended, and
approved dose initiation of quetiapine. Using quetiapine for
both groupsmadedose initiation the only differencebetween
the two treatment groups. The total study period for each
patientwas14days. Patientswere randomlyassigned to rapid
or conventional initiation groups in a ratio of 3:1. No violence
or other emergent condition was observed in any patient in
the rapid initiation group. The initial dose of quetiapine in the
rapid initiation group was 200 mg once daily with increments
of 100 mg twicea day thus reaching a dose of 800 mgonDay 4.
A flexible dosing schedule of 400e800 mg/d from Day 5 to
Day 14 was then applied. A flexible dosing schedule of
400e800 mg/d from Day 6 to Day 14 was then followed.
Assessments
Safety and tolerability
The following safety-related variables were measured: heart
rate and blood pressure, including sitting diastolic blood
pressure, standing diastolic blood pressure, sitting systolic
blood pressure, and standing systolic blood pressure. All
were measured within 1 hour of administration of each dose
of quetiapine for the first 7 days and on Day 14 or during the
last visit. Electrocardiography was conducted during the
screening visit (Day 0) and on Day 14 or during the last visit.
Extrapyramidal symptoms (EPSs) were also recorded using
the Barnes Akathisia Rating Scale (BARS), the Simpson-Angus
Scale (SAS), and by observation of any adverse events once
a day for the first 7 days and on Day 14 or during the last visit
[5,6]. All patients were examined by psychiatrists.
Efficacy
Drug efficacy was assessed using the CGI-S Scale and the
Positive and Negative Syndrome Scale (PANSS) on Day
0 (screening), Day 1 (baseline), Day 5, Day 7, and Day 14 [7].
Statistical analysis
All data that were collected in the study were summarized
for each treatment group using tables, graphs, and
summary statistics. The data that were collected during
Week 1 specifically targeted the analysis of safety and
tolerability. The differences between the treatment groups
in terms of efficacy were estimated by analysis of covari-
ance, with the baseline score and treatment group assign-
ment as covariables. For dropouts, the last observation was
carried forward. Continuous variables were compared using
Student t test or a paired-sample t test and correlated using
partial correlation. Categorical variables were compared
using the Chi-square test. A two-tailed p value less than
0.05 was regarded as statistically significant.
Results
Baseline characteristics
A total of 40 patients were screened, and all were found to
be eligible for participation in the study. Patients in the
Table 1 Baseline characteristics of all randomized patients
Characteristics Rapid initiation (nZ 30) Conventional initiation (nZ 10)
Mean SD Mean SD
Height (cm) 164.7 8.3 160.6 8.7
Weight (kg) 66.2 12.9 62.9 11.9
Body mass index (kg/m2) 24.5 4.8 24.2 3.0
Sitting systolic blood pressure (mmHg) 115.3 15.7 114.7 11.6
Standing systolic blood pressure (mmHg) 111.9 13.6 114.4 11.5
Sitting diastolic blood pressure (mmHg) 72.9 10.6 70.2 8.3
Standing diastolic blood pressure (mmHg) 73.4 11.5 73.1 7.7
Heart rate* (beats/min) 87.1 16.3 75.0 14.9
Barnes Akathisia Rating Scale 2.1 3.1 0.9 1.7
Simpson-Angus Scale 3.2 3.6 2.1 2.4
Clinical Global ImpressiondSeverity of Illness 5.1 0.9 5.0 1.1
PANSS total score 87.6 14.4 87.0 14.7
PANSS positive score 23.4 4.8 24.0 4.8
PANSS negative score 20.9 5.7 18.8 4.2
*Statistically significant (p< 0.05).
PANSSZ Positive and Negative Syndrome Scale; SDZ standard deviation.
Table 2 Summary of adverse events reported during the








n (%) n (%)
Gastrointestinal disorders
Constipation 12 (40) 0 (0.0) 0.019*
Nervous system disorders
Gait disturbance 2 (6.7) 1 (10.0) 1.000
Akathisia 2 (6.7) 0 (0.0) 1.000
Dizziness 3 (10.0) 1 (10.0) 1.000
Somnolence 6 (20.0) 1 (10.0) 0.656
*Statistically significant (p< 0.05).
510 C.-C. Hsiao et al.rapid initiation group (nZ 30) were aged from 22 years to
57 years (mean standard deviation, 38.3 10.1) and
included 12 women (40%). Patients in the conventional
initiation group were aged from 29 years to 58 years (mean,
42.7 9.7) and included six women (60%). Table 1 presents
the baseline characteristics of all 40 randomly assigned
patients. No significant differences were found in patient
characteristics or baseline parameters, except for the
heart rate (pZ 0.045). A significant difference in the
quetiapine dose at Day 14 existed between the rapid initi-
ation group (696.9 174.2 mg/d) and the conventional
initiation group (515.0 305.6 mg/d) (pZ 0.026).
Concomitant medications
The most common classes of drugs that were permitted by
the protocol, if the patients had received stable doses for
at least 4 weeks before entry into the study, and were,
therefore, taken throughout the study, were sedatives,
laxatives, and psychotropic medications.
Safety and tolerability
Four patients (13%) in the rapid initiation group did not
complete the study because of hypersomnia in one patient
and worsening of the underlying condition in three
patients. Three patients (30%) in the conventional initiation
group did not complete the study because of worsening of
the underlying condition in one patient and withdrawal of
consent by two patients.
The primary endpoints were dropouts attributed to
adverse events and the total number of adverse events
reported by the end of Week 1. Only one patient in the
rapid initiation group dropped out because of an adverse
event (hypersomnia), and the investigator judged this
event to be treatment related. Table 2 summarizes the
adverse events, all of which occurred with an incidence
greater than 5% during Week 1. In the rapid initiation group,the most frequently reported adverse event was con-
stipation [12 patients (40%)]. The difference between the
incidences of adverse events in the groups during Week 1
was not significant, except in the case of constipation
(pZ 0.019). The incidence of extrapyramidal adverse
events that are commonly associated with antipsychotics,
such as gait disturbance, akathisia, and tremor, did not
differ significantly between the two groups. In the first
week, 18 patients (60%) in the rapid initiation group and
five patients (50%) in the conventional initiation group
reported treatment-related adverse events, indicating
statistical difference between the groups (pZ 0.154). The
between-group differences in sitting diastolic blood pres-
sure, standing diastolic blood pressure, sitting systolic
blood pressure, and standing systolic blood pressure were
not significant at any time during the study.
The baseline heart rates that were measured while the
patients were seated differed significantly between the
rapid and conventional initiation groups (pZ 0.045). The
change in the heart rate from the baseline was not
Table 3 Mean change in BARS and SAS scores from baseline to study end (LOCF)
Scale Mean change from baseline (SD)
Day 5 Day 7 Day 14
BARS
Rapid initiation (nZ 30) 1.37 (2.63)* 1.54 (3.08)* 1.73 (2.95)*
Conventional initiation (nZ 10) 0.63 (1.41) 0.13 (0.35) 0.30 (0.48)
SAS
Rapid initiation (nZ 30) 2.00 (3.18)* 2.69 (3.54)* 2.60 (3.88)*
Conventional initiation (nZ 10) 1.50 (2.93) 0.75 (3.06) 0.90 (2.88)
*Scale score reduced significantly from baseline (p< 0.05).
BARSZ Barnes Akathisia Rating Scale; SASZ Simpson-Angus Scale; SDZ standard deviation.
Rapid initiation of quetiapine 511significant in either group at any point in the study. The
difference between the changes in the heart rates of the
patients in the two groups from the baseline values was not
significant at any visit. The shift from normal to abnormal
electrocardiography and vice versa was not significant
(pZ 1.00 in the rapid initiation group and pZ 0.56 in the
conventional initiation group).
Incidence of adverse events (days 1e14)
Adverse events were reported by 93.3% of the patients in
the rapid initiation group and by 80.0% of the patients in
the conventional initiation group, but none of the reported
adverse events was serious. The most frequently reported
adverse event was constipation (43.3% in the rapid initia-
tion group and 10.0% in the conventional initiation group).
In the rapid initiation group, the following adverse
events were reported with a frequency greater than 10%:
alteration of mood (23.3%), somnolence (20.0%), dizziness
(16.7%), anxiety (13.3%), and hypersomnia (10%). In the
conventional initiation group, the following adverse events
were reported with a frequency greater than 10%: hyper-
somnia (30.0%), alteration of mood (20.0%), diarrhea
(20.0%), somnolence (10.0%), gait disturbance (10.0%),
dizziness (10.0%), aggression (10.0%), anxiety (10.0%),
eczema (10.0%), and skin exfoliation (10.0%).
The incidence rates of expected adverse events, such




Rapid initiation (nZ 30) 0.73 (0.58)*
Conventional initiation (nZ 10) 0.70 (0.95)*
PANSS positive score
Rapid initiation (nZ 30) 3.40 (3.70)*
Conventional initiation (nZ 10) 4.20 (4.57)*
PANSS negative score
Rapid initiation (nZ 30) 2.57 (3.21)*
Conventional initiation (nZ 10) 0.80 (2.35)
*Scale score reduced significantly from baseline (p< 0.05).
CGI-SZ Clinical Global ImpressiondSeverity of Illness; PANSSZ Posithypersomnia, and tremor did not differ significantly
different the two groups. Treatment-related adverse events
were observed in 20 patients (66.7%) in the rapid initiation
group and in five patients (50%) in the conventional initia-
tion group.BARS and SAS
Table 3 shows that the rapid initiation group had signifi-
cantly continuous decrease in the BARS and SAS scores from
their baseline values on Day 5, Day 7, and Day 14. It is
different between the two groups.Efficacy
Table 4 shows that the rapid initiation group exhibited
significant improvement in the mean PANSS negative score
from the baseline value on Day 5, Day 7, and Day 14. Only
the rapid initiation group maintained significant CGI-S score
improvements and PANSS positive score improvements until
the end of the study.Discussion
This investigation compared the safety and tolerability of
a rapid initiation regimen with a higher dose of quetiapineat Day 5, Day 7, and Day 14 (LOCF)
Mean change from baseline (SD)
Day 7 Day 14
1.13 (0.86)* 1.50 (1.01)*
0.80 (0.92)* 0.80 (1.48)
4.77 (4.72)* 6.37 (6.08)*
4.90 (4.46)* 4.30 (7.39)
3.97 (3.84)* 5.47 (4.39)*
1.50 (2.76) 2.30 (3.92)
ive and Negative Syndrome Scale; SDZ standard deviation.
512 C.-C. Hsiao et al.than that conventionally used with those of the current
conventional initiation regimen that is approved in Taiwan.
Numerous clinical investigations have supported the use
of a rapid dose initiation regimen with a higher dose of
quetiapine than that conventionally used [4,8e12]. Smith
et al. [4] reported that patients for whom quetiapine was
titrated to 400 mg/d by Day 2 had the same adverse events
as patients who followed the usual 5-day initiation
schedule. In a study of hospitalized patients with psychoses,
doses of quetiapine up to 1,600 mg/d were effective and
well tolerated, with no evidence of EPS [12]. Ganesan et al.
[9] observed that, for patients with psychosis who exhibited
aggression in an emergency setting, treatment with que-
tiapine at doses up to 1,000 mg/d reduced aggressive
behavior, including aggression against others, by the second
day of treatment. Together with results concerning safety,
the data herein suggest that a rapid initiation regimen with
a higher dose of quetiapine that is conventionally used is
suitable in acute cases. Significant improvements in the
mean CGI-S score, PANSS positive score, and PANSS negative
score from their baselines were observed on Day 14 only for
the rapid initiation group and not for the conventional
initiation group.
In the present study, the incidence of adverse events
during Week 1 was of particular interest because the
outcome of the rapid initiation schedule was most evident
during this period. The results of this study reveal that the
incidence of adverse events, except constipation, did not
differ significantly between the rapid and conventional
initiation schedules. The incidence of constipation was
significantly higher in the rapid initiation group during Week
1. Raedler et al. [13] found that treatment with higher
doses of quetiapine was associated with constipation.
N-desalkyl quetiapine, a metabolite of quetiapine, is an
antagonist of the muscarinic 1, 3, and 5 receptors. The
possible contribution of this metabolite to constipation has
been discussed [14]. However, severe constipation did not
cause any patient in the rapid initiation group to drop out.
Somnolence is regarded as a common side effect of
quetiapine treatment, but no evidence suggests that the
conventional initiation schedule reduces the incidence of
somnolence compared with the rapid initiation schedule
[15,16]. A previous study of rapid dose titration with high
doses of quetiapine for treating acute psychotic cases
revealed that the most common adverse event was seda-
tion. In another such study, however, only one patient
experienced transient somnolence [17,18]. In the present
study, the incidence of somnolence did not differ signifi-
cantly between the two initiation schedules, but one
patient in the rapid initiation group dropped out because of
intolerable somnolence. No orthostatic hypotension was
reported by any patient in this study, which is consistent
with the results of a study of rapid initiation of quetiapine
by Hatim et al. [10].
At all time points, the groups did not differ in either the
BARS or the SAS score, but the BARS and SAS scores declined
significantly from baseline only in the rapid initiation group.
This finding is notable because drug-induced EPSs are
known to compromise adherence to medication schedules
[19]. Some findings in other investigations support the claim
that switching to quetiapine reduces pre-existing neuro-
leptic-induced extrapyramidal side effects, causing, inparticular, a significant reduction in Parkinsonism and
akathisia [20].
Although no significant intergroup difference in the CGI-
S scores and PANSS positive scores was observed,
improvements in the CGI-S scores and PANSS positive scores
were maintained from the first week until the end of the
study only in the rapid initiation group. The PANSS negative
score also improved significantly throughout the present
study only for the rapid initiation group.
The first limitation of this study is the small sample size
and the random assignment of patients in a ratio of 3:1 to
rapid and conventional initiation groups, which resulted in
low statistical power, which was insufficient to detect
differences. The second limitation was the failure to
prohibit the use of concomitant psychotropic drugs and
sedatives; however, this was not ethically possible because
our patients had underlying diseases that required the use
of these concomitant medications. In an attempt to control
this variable, all concomitant medications were stably
dosed for 4 weeks before randomization, and no significant
difference in this parameter existed between the two
groups. The most common concomitant medication was
benzodiazepam. The third limitation was the significant
difference between the quetiapine doses of the rapid and
conventional initiation groups at Day 14, which may have
affected the efficacy data for the two groups at the end of
study. Recent investigations have suggested that higher
doses of quetiapine have greater therapeutic efficacy [13].
Other limitations were an excessively short washout period
and rater bias that was associated with the open trial
design.
In conclusion, in a 2-week study of patients with
schizophrenia or schizoaffective disorders, a rapid initia-
tion regimen with a higher dose of quetiapine than that
conventionally used (up to 800 mg/d by Day 4) was well
tolerated with an acceptable safety profile and did not
compromise efficacy relative to the conventional initiation
regimen.Acknowledgments
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